Boston, MA, July 28, 2014 (GLOBE NEWSWIRE) -- Inform Genomics, Inc, a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products, today announced the appointment of Carl de Moor, PhD, as Chief Technology Officer.
"We are very pleased to have Carl join Inform Genomics as a member of our senior management and executive team. Carl's vast industry and academic expertise in the biostatistics and health outcomes space will significantly aid Inform Genomics as we continue to grow the Company," said Ed Rubenstein, MD, President and CEO of Inform Genomics.
Dr de Moor has more than 25 years of experience in epidemiology, biostatistics, and health outcomes research. His areas of expertise include pharmacoepidemiologic study designs, patient-reported outcome (PRO) assessment methodology and analysis, predictive modeling, longitudinal and time varying modeling, correlated data methods, and multivariate methods.
Prior to joining Inform Genomics, Dr de Moor was Senior Principal Epidemiology and Lead, Epidemiology Center of Excellence, at IMS Health, where he designed and directed retrospective epidemiologic research. He has served in several executive roles in industry, including Vice President of Epidemiology at MAPI, a late-phase CRO; Executive Director Epidemiology and Health Outcomes at PPD, Inc.; and Vice President of Health Outcomes and Pharmacoeconomics at Supportive Oncology Services, Inc, an oncology CRO.
About Inform Genomics
Inform Genomics, Inc, is a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products that are designed to predict, with a high degree of accuracy, clinically important outcomes that assist physicians and their patients in making individualized medical decisions. Its lead development program is in oncology supportive care, with two major products currently in development--OnPART™ and HSCT/Mucositis™--designed not only to predict a patient's risk for developing common chemotherapy-related side effects, but also to assess a patient's willingness to tolerate those side effects. The Company's novel, IP-protected technology platform capitalizes on big data storage/memory and sophisticated cloud computing technologies. It consists of proprietary Bayesian networks and other advanced bioinformatic analytics combined with validated patient assessment tools. The Company's analytics discover interactions of genes and single nucleotide polymorphisms (SNPs) that can predict clinical outcomes. Inform Genomics' goal is to be a trusted partner to health care practitioners so that they, together with their patients, can make optimal health care choices based on an individual patient's needs and values. For more information, please visit www.informgenomics.com.